PubMed

Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study.

Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, Lau KP, Siu SC, Li JK, Yeung VT, Leung WY, Tong PC; SURE Study Group.

Diabetes Care. 2009 Jun;32(6):977-82.PMID: 19460913 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy.

Leung WY, So WY, Tong PC, Chan NN, Chan JC.

Am J Med. 2005 Dec;118(12):1414.PMID: 16378791 [PubMed - indexed for MEDLINE]Related articles

Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial.

Ménard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, Ardilouze JL.

CMAJ. 2005 Dec 6;173(12):1457-66. Epub 2005 Nov 17.PMID: 16293781 [PubMed - indexed for MEDLINE]Related articlesFree article

Analysis of metabolic parameters as predictors of risk in the RENAAL study.

Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S, Brenner BM; RENAAL Study.

Diabetes Care. 2003 May;26(5):1402-7.PMID: 12716796 [PubMed - indexed for MEDLINE]Related articlesFree article

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.PMID: 14586737 [PubMed - indexed for MEDLINE]Related articles

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).

Davis TM, Cull CA, Holman RR; U.K. Prospective Diabetes Study (UKPDS) Group.

Diabetes Care. 2001 Jul;24(7):1167-74.PMID: 11423497 [PubMed - indexed for MEDLINE]Related articlesFree article

Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.

Martínez-Ramírez HR, Jalomo-Martínez B, Cortés-Sanabria L, Rojas-Campos E, Barragán G, Alfaro G, Cueto-Manzano AM.

Am J Kidney Dis. 2006 Jan;47(1):78-87.PMID: 16377388 [PubMed - indexed for MEDLINE]Related articles

Effects of protocol-driven care versus usual outpatient clinic care on survival rates in patients with type 2 diabetes.

So WY, Tong PC, Ko GT, Leung WY, Chow CC, Yeung VT, Chan WB, Critchley JA, Cockram CS, Chan JC.

Am J Manag Care. 2003 Sep;9(9):606-15.PMID: 14527106 [PubMed - indexed for MEDLINE]Related articlesFree article

A comprehensive assessment of the avoidability of long-term complications of diabetes. A case-control study. SID-AMD Italian Study Group for the Implementation of the St. Vincent Declaration.

Nicolucci A, Cavaliere D, Scorpiglione N, Carinci F, Capani F, Tognoni G, Benedetti MM.

Diabetes Care. 1996 Sep;19(9):927-33.PMID: 8875084 [PubMed - indexed for MEDLINE]Related articles

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.PMID: 7587846 [PubMed - indexed for MEDLINE]Related articles

Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings.

Minutolo R, Sasso FC, Chiodini P, Cianciaruso B, Carbonara O, Zamboli P, Tirino G, Pota A, Torella R, Conte G, De Nicola L.

J Hypertens. 2006 Aug;24(8):1655-61.PMID: 16877970 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.

Kennedy L, Herman WH, Strange P, Harris A; GOAL AIC Team.

Diabetes Care. 2006 Jan;29(1):1-8.PMID: 16373887 [PubMed - indexed for MEDLINE]Related articlesFree article

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

[No authors listed]

Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602. PMID: 9742976 [PubMed - indexed for MEDLINE]Related articles

Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.

Brocco E, Velussi M, Cernigoi AM, Abaterusso C, Bruseghin M, Carraro A, Sambataro M, Piarulli F, Sfriso A, Nosadini R.

J Nephrol. 2001 Nov-Dec;14(6):461-71.PMID: 11783602 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

Rate of decline of GFR and progression of vascular disease in type 2 diabetic patients with diabetic or vascular nephropathy during the last three years before starting dialysis therapy.

Biesenbach G, Schmekal B, Pieringer H, Janko O.

Kidney Blood Press Res. 2006;29(5):267-72. Epub 2006 Oct 11.PMID: 17035711 [PubMed - indexed for MEDLINE]Related articles

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

Nephrol Dial Transplant. 2000 Apr;15(4):487-97.PMID: 10727543 [PubMed - indexed for MEDLINE]Related articlesFree article

Prospective study on renal outcome of IgA nephropathy superimposed on diabetic glomerulosclerosis in type 2 diabetic patients.

Mak SK, Wong PN, Lo KY, Tong GM, Wong AK.

Nephrol Dial Transplant. 2001 Jun;16(6):1183-8.PMID: 11390718 [PubMed - indexed for MEDLINE]Related articlesFree article